Fusion Antibodies (FAB) Share Price, News & Analysis

Company Overview

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue. The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation. Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process. The global monoclonal antibody therapeutics market was valued at $186 billion in 2021 and is forecast to surpass $445 billion in 2028, an increase at a CAGR of 13.2 per cent. for the period 2022 to 2028. Approximately 150 monoclonal antibody therapies are approved and marketed globally as of June 2022 with the top four antibody drugs each having sales of more than $3 bn in 2021.

Key Stats

• Today's Range: 6 to 7
• 50-Day Range: 5.90 to 7.48
• 52-Week Range: 2.80 to 12
• Volume: 836,171 shs
• Average Volume: 1.01 million shs
• Market Capitalization: £6.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FAB Stock Analysis - Frequently Asked Questions

How have FAB shares performed this year?

Fusion Antibodies' stock was trading at GBX 7.16 at the start of the year. Since then, FAB shares have decreased by 6.5% and is now trading at GBX 6.69.
View the best growth stocks for 2025 here.

How were Fusion Antibodies' earnings last quarter?

Fusion Antibodies plc (LON:FAB) posted its quarterly earnings results on Tuesday, November, 19th. The company reported ($0.80) earnings per share for the quarter. Fusion Antibodies had a negative trailing twelve-month return on equity of 137.11% and a negative net margin of 195.95%.

How do I buy shares of Fusion Antibodies?

Shares of FAB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Fusion Antibodies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Fusion Antibodies investors own include 4D pharma (DDDD), Omega Diagnostics Group (ODX), Tullow Oil (TLW), Active Energy Group (AEG), B&M European Value Retail (BME), BP (BP) and Coats Group (COA).

Company Calendar

• Last Earnings: 11/19/2024
• Today: 6/21/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:FAB
• CIK: N/A
• Web: fusionantibodies.com
• Phone: +44-28-90432800
• Fax: N/A
• Employees: 48
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (4.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£4.10 million
• Net Margins: -195.95%
• Pretax Margin: N/A
• Return on Equity: -137.11%
• Return on Assets: -63.78%

Debt

• Debt-to-Equity Ratio: 2.40
• Current Ratio: 3.87
• Quick Ratio: 2.36

Sales & Book Value

• Annual Sales: £2.09 million
• Price / Sales: 3.01
• Cash Flow: GBX 0.74 per share
• Price / Cash Flow: 9.02
• Book Value: GBX 3.51 per share
• Price / Book: 1.91

Miscellaneous

• Outstanding Shares: 94,055,867
• Free Float: N/A
• Market Cap: £6.30 million
• Optionable: Not Optionable
• Beta: 0.49